Evidence map›Paper›PMID 42889080›Full record

ArticleFrontiers in immunology2026

Identification of a novel inflammatory mast cell subpopulation in triple-negative breast cancer.

Zehan Li, Ziqing Wu, Lingxin Zeng, Chuzhong Wei, Huazhen Wu, Huisi Qiu, Jianping Chen, Pingmei Zhang, Yuxiao Tian, Fanghui Bian and 14 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Zehan Li *Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Ziqing Wu *Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Lingxin Zeng *Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Chuzhong Wei *Department of Urology and Institute of Urology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Huazhen Wu *Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Huisi QiuDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Jianping ChenDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Pingmei ZhangDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Yuxiao TianDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Fanghui BianDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Jiemin LiangDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Dongqian LiDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Muyan LiuDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Zhiying LiDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Yuyi LiuDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Meiyi LiDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Xiangfeng CenDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Lihuan ZhouDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Huodi ChenDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Huijuan JiangDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Haosheng LiDepartment of Medical Imaging, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, Guangdong, China.
Xin WangDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Ruiming TangDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Song ZhuDepartment of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) is associated with poor therapeutic outcomes, and increasing attention has been directed toward the tumor microenvironment (TME). Mast cells are an important component of the TME, yet their heterogeneity and functional roles in TNBC remain incompletely understood. Methods: Single-cell RNA sequencing data of TNBC were analyzed using the Seurat pipeline. Mast cells were extracted and re-clustered, and the subpopulations were characterized by functional enrichment, transcription factor, pseudotime, drug sensitivity, and cell-cell communication analyses. The role of the inflammatory subpopulation was further examined using an in silico virtual knockout approach and validated in a 4T1 subcutaneous tumor model in BALB/c mice. Results: Four transcriptionally distinct mast cell subpopulations were identified. Among them, the C4 subpopulation exhibited a pronounced inflammatory signature and was highly enriched in the NF-κB pathway. C4 was predicted to have lower sensitivity to several first-line chemotherapeutic agents and was associated with an unfavorable treatment response. Cell-cell communication analysis suggested that C4 may suppress CD8 Conclusions: We identified an inflammation-associated mast cell subpopulation (C4) that may contribute to TNBC progression, providing a potential target for future therapeutic exploration.

Indexed as

Mast CellsTriple Negative Breast NeoplasmsAnimalsCell CommunicationCell Line, TumorFemaleHumansInflammationMiceMice, Inbred BALB CNF-kappa BSingle-Cell Gene Expression AnalysisTumor MicroenvironmentNF-kappa Bmast cellsNF-κBsingle-cell RNA sequencingtriple-negative breast cancertumor immunitytumor microenvironment

Identifiers

PMID42889080
PMCPMC13668803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.